Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
2.040
-0.040 (-1.92%)
At close: Jul 31, 2025, 4:00 PM
2.060
+0.020 (0.98%)
After-hours: Jul 31, 2025, 7:23 PM EDT
Company Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.
The company was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Faheem Hasnain |
Contact Details
Address: 3115 Merryfield Row, Suite 120 San Diego, California 92121 United States | |
| Phone | 858 684 1300 |
| Website | gossamerbio.com |
Stock Details
| Ticker Symbol | GOSS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001728117 |
| CUSIP Number | 38341P102 |
| ISIN Number | US38341P1021 |
| Employer ID | 47-5461709 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Faheem Hasnain | Co-Founder, Chief Executive Officer, President and Chairman |
| Bryan Giraudo | Chief Operating Officer and Chief Financial Officer |
| Dr. Richard Aranda M.D. | Chief Medical Officer |
| Christian Waage J.D. | Executive Vice President of Technical Operations and Administration |
| Jeff Boerneke | General Counsel and Secretary |
| Jeanine Anthony | Senior Vice President of Marketing |
| Deanna Weber | Senior Vice President of Human Resources |
| Dr. Robert F. Roscigno Ph.D. | Senior Vice President of Clinical Development of Pulmonary Vascular Disease |
| Caryn L. Peterson | Executive Vice President of Regulatory Affairs |
| Matt Cravets | Senior Vice President of Biometrics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jul 17, 2025 | SCHEDULE 13G | Filing |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 16, 2025 | 8-K | Current Report |
| May 15, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |